UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/518,668	08/22/2005	Ulrike Wachendorff-Neumann	CS-8438/LeA 36,144	6799
	7590 , 02/23/200 SLER, GOLDSTEIN &	EXAMINER		
•	RK AVENUE, N.W.	QAZI, SABIHA NAIM		
WASHINGIO	1, DC 20003		ART UNIT	PAPER NUMBER
		1616		
SHORTENED STATUTORY	Y PERIOD OF RESPONSE	MAIL DATE	DELIVERY MODE	
3 MONTHS		02/23/2007	PAPER	

Please find below and/or attached an Office communication concerning this application or proceeding.

If NO period for reply is specified above, the maximum statutory period will apply and will expire 6 MONTHS from the mailing date of this communication.

Office Action Summary		Application No.	Applicant(s)			
		10/518,668	WACHENDORFF-NEUMANN ET AL.			
		Examiner	Art Unit			
		Sabiha Qazi	1616			
Period fo	The MAILING DATE of this communication app or Reply	ears on the cover sheet with the c	orrespondence address			
WHIC - Exter after - If NO - Failu Any r	ORTENED STATUTORY PERIOD FOR REPLY CHEVER IS LONGER, FROM THE MAILING DATE of the may be available under the provisions of 37 CFR 1.13 SIX (6) MONTHS from the mailing date of this communication. It is period for reply is specified above, the maximum statutory period were to reply within the set or extended period for reply will, by statute, reply received by the Office later than three months after the mailing and patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION 36(a). In no event, however, may a reply be tim vill apply and will expire SIX (6) MONTHS from cause the application to become ABANDONE	I. lely filed the mailing date of this communication. D (35 U.S.C. § 133).			
Status						
1)🖂	Responsive to communication(s) filed on 26 Ja	nuary 2007.				
2a) <u></u> □	This action is FINAL . 2b)⊠ This action is non-final.					
3)	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is					
closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213.						
Dispositi	on of Claims					
5)□ 6)⊠ 7)□	Claim(s) <u>9-15</u> is/are pending in the application. 4a) Of the above claim(s) is/are withdraw Claim(s) is/are allowed. Claim(s) <u>9-15</u> is/are rejected. Claim(s) is/are objected to. Claim(s) are subject to restriction and/or	vn from consideration.				
Applicati	on Papers					
10) 🔲 -	The specification is objected to by the Examiner The drawing(s) filed on is/are: a) access Applicant may not request that any objection to the correction and the correction of the co	epted or b) objected to by the Edrawing(s) be held in abeyance. See on is required if the drawing(s) is obj	e 37 CFR 1.85(a). ected to. See 37 CFR 1.121(d).			
Priority u	nder 35 U.S.C. § 119					
12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No. 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received.						
Attachment	(5)	•				
1) Notice 2) Notice 3) Inform	e of References Cited (PTO-892) e of Draftsperson's Patent Drawing Review (PTO-948) nation Disclosure Statement(s) (PTO/SB/08) No(s)/Mail Date	4) Interview Summary Paper No(s)/Mail Da 5) Notice of Informal Pa 6) Other:	te			

Non-Final Office Action

Claims 9-15 are pending. No claim is allowed at this time.

Summary of this Office Action dated Monday, February 19, 2007

- 1. Information Disclosure Statement
- 2. Copending Applications
- 3. Specification
- 4. 35 USC § 103(a) Rejection
- 5. Response to Remarks
- 6. Communication

Continued Examination Under 37 CFR 1.114

A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 01/26/2007 has been entered.

Information Disclosure Statement

The listing of references in the specification is not a proper information disclosure statement. 37 CFR 1.98(b) requires a list of all patents, publications, or other information submitted for consideration by the Office, and MPEP § 609.04(a) states, "the list may not be incorporated into the specification but must be submitted in a separate paper." Therefore, unless the references have been cited by the examiner on form PTO-892, they have not been considered.

Copending Applications

Applicants must bring to the attention of the examiner, or other Office official involved with the examination of a particular application, information within their knowledge as to other copending United States applications, which are "material to

patentability" of the application in question. MPEP 2001.06(b). See Dayco Products Inc. v. Total Containment Inc., 66 USPQ2d 1801 (CA FC 2003).

Specification

The specification has not been checked to the extent necessary to determine the presence of all possible minor errors. Applicant's cooperation is requested in correcting any errors of which applicant may become aware in the specification.

Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

The factual inquiries set forth in *Graham* v. *John Deere Co.*, 383 U.S. 1, 148 USPQ 459 (1966), that are applied for establishing a background for determining obviousness under 35 U.S.C. 103(a) are summarized as follows:

- 1. Determining the scope and contents of the prior art.
- 2. Ascertaining the differences between the prior art and the claims at issue.
- 3. Resolving the level of ordinary skill in the pertinent art.
- 4. Considering objective evidence present in the application indicating obviousness or nonobviousness.

Application/Control Number: 10/518,668

Art Unit: 1616

This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(e), (f) or (g) prior art under 35 U.S.C. 103(a).

Claims 9-15 are rejected under 35 U.S.C. 103(a) as being unpatentable over ISENRING et al. (United States Patent No. 6407,100), HEINEMANN et al. (US Patent 6,103,717) and JAUTELAT et al. (US Patent 5,789,430). All these references teach the compounds as antimicrobial agents, which embraces Applicant's claimed invention.

ISENRING teaches trifloxystrobin as fungicide. See the entire document especially lines 10-20 in column 1, lines 34-67 in column 6, abstract, and examples.

HEINEMANN teaches fuoxastrobin as antimicrobial agent. See the entire document especially examples 1-3 in column 15 and 16. These compounds have powerful microbial activity and are useful for controlling undesired microorganism. See lines 39-67 in column 10, lines 1-60 in column 11.

JAUTELAT teaches prothioconazole as microbicides. See the entire document especially example 1 in column 35, lines 27-64 in column 29, lines 1-55 in column 30.

Instant claims differ from the reference in claiming the combination of all three known compounds useful as antimicrobial and antifungal agents.

It would have been obvious to one skilled in the art at the time the invention was made to combine known compounds for the same purpose in expectation to get a better activity. Since all the above cited reference teach the active compounds It is *prima facie* obvious to combine two or more compositions each of which is taught by the prior art to be useful for the same purpose in order to form a new composition that is to be used for the very same purpose; the idea of combining them flows logically from their having been individually taught in the prior art. *In re Kerkhoven*, 205 USPQ 1069. No synergism has been noted.

In absence of any criticality and/or unexpected results presently claimed subject matter, which is the combination of known compounds, would have been obvious at the time of invention to one skilled in the art.

In the light of the forgoing discussion, the Examiner's ultimate legal conclusion is that the subject matter defined by the instant claims would have been obvious within the meaning of 35 U.S.C. 103(a).

Art Unit: 1616

Data in Specification

The synergism as presented in the specification is not in claims. Claims are drawn to simply combination of the compounds. The Examiner has considered data presented in specification on page 11 in view of the remarks filed by Applicants. The application of the compounds (I), (II) and (III) are 100 g/ha and efficacy is 56, 56 and 67 percent respectively. It is unclear how this data relates to mixture where 25, 50 and 25 are g/ha and 78 percent is efficacy. Furthermore, how the number calculated is 78 when the ratio is 1:2:1. Applicant is requested to explain in detail in case they would like to amend the claims to synergistic amounts, that how this data represents a synergism.

Response to Remarks

- Arguments were fully considered but were not found persuasive. Examiner respectfully disagrees with basis of the arguments because the when two parts of component (II) (prothioconazole) is used the ratio should be divided by 4. As has been said in our earlier office action that no synergism was found in the data presented in the specification on page 11. Efficacy in % is 56 +56+67. When calculating what is expected 56+56+67 should be devided by three.
- Since the ratio of components used in present invention is 1:2:1. When component II is doubled than the total will be 56+(2x56)+67. This number should be divided 4 and not 3 for expected results. There is no synergism.

Application/Control Number: 10/518,668

Art Unit: 1616

• Applicant is kindly requested to explain more about the data presented on page

11 of the specification.

Communication

Any inquiry concerning this communication or earlier communications from the

examiner should be directed to Sabiha Qazi, Ph.D. whose telephone number is 571-

272-0622. The examiner can normally be reached on any business day.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's

supervisor, Johann Richter, Ph.D. can be reached on 571-272-0646. The fax phone

number for the organization where this application or proceeding is assigned is 571-

273-8300.

Information regarding the status of an application may be obtained from the

Patent Application Information Retrieval (PAIR) system. Status information for

published applications may be obtained from either Private PAIR or Public PAIR.

Status information for unpublished applications is available through Private PAIR only.

For more information about the PAIR system, see http://pair-direct.uspto.gov. Should

you have questions on access to the Private PAIR system, contact the Electronic

Business Center (EBC) at 866-217-9197 (toll-free).

SABIHA QAZI, PH.D PRIMARY EXAMINER

Page 8